Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | PKLR | P30613 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542998 | 0.90 | ALDH1A1 (0.79) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL17007497 | 0.89 | ALDH1A1 (0.78) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| Hydrochloric Acid SCHEMBL17007509 | 0.88 | ALDH1A1 (0.76) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL17922962 | 0.87 | ALDH1A1 (0.75) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL17007492 | 0.87 | ALDH1A1 (0.75) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL17007503 | 0.85 | DHCR7 (0.75) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL1044915 | 0.85 | HTT (0.96) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL8508293 | 0.83 | HTT (1.00) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL4555472 | 0.83 | HTT (1.00) | ALDH1A1CYP2D6CYP2C19KDM4EGAA | |
| SCHEMBL23178943 | 0.82 | PKM (0.75) | ALDH1A1CYP2D6CYP2C19KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| CN-105873913-B | Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins | 得克萨斯系统大学评议会 | 2019-12-03 | — | — | CN | disclosed |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2019-09-05 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018022904-A2 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-02-01 | — | — | WO | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| CN-105873913-A | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | 得克萨斯系统大学评议会 | 2016-08-17 | — | — | CN | disclosed |
| EP-3044218-A2 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | Board Of Regents Of the University Of Texas System (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ALDH1A1 4595/4885CYP2D6 4783/4885CYP2C19 4237/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | ALDH1A1 2402/4885CYP2D6 4594/4885CYP2C19 4799/4885 |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ALDH1A1 4595/4885CYP2D6 4783/4885CYP2C19 4237/4885 |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | SREBF1, SREBF2, EBPL | ALDH1A1 4063/4885CYP2D6 4199/4885CYP2C19 4602/4885 |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | ALDH1A1 2402/4885CYP2D6 4594/4885CYP2C19 4799/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | ALDH1A1 4595/4885CYP2D6 4783/4885CYP2C19 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.